A One Nucleus and Lonza symposium

Digitally delivered | Monday 29 March 2021

Gain insight and discuss the challenges of early stage biopharmaceutical development

One Nucleus and Lonza Biologics are pleased to invite you to join us for a complimentary virtual symposium to gain insight from experts in the different approaches and techniques to successfully progress biotherapeutic candidates from discovery to the clinic. Enjoy updates on enhancements to new and established technologies enabling translational research. The day includes talks from industry experts, local companies and technical specialists from Lonza.

Our networking breaks and virtual lunch offers the opportunity to speak with fellow scientists, presenters and Lonza specialists. In the days following the symposium, you will have the opportunity to book a virtual consultancy session with one of Lonza’s technical experts. 

 

Register Here

 

Agenda (U.K. Time)

 
08.30 – 08.45

Welcome and symposium overview 
Dr. Tony Jones, CEO One Nucleus | Lonza representative
Moderator: Dr. Hari Kumar | Pharmaceutical Executive; Independent Board Member; former CEO Adheron Therapeutics

08.45 – 09.25

Keynote Presentation 
Potent neutralisation of SARS-CoV-2 by nanobodies that block binding to ACE2
Professor Ray Owens | Head of Protein Production – UK (PPUK), Rosalind Franklin Institute, University of Oxford

09.25 – 09:50 Right first time: optimize and de-risk your early development journey
Dr. Yvette Stallwood | Head of Applied Protein Services, Lonza
09:50 – 10.15 Bispecific Discovery: Where do we start and where are we going? 
Dr. Ed McGowan, Director of Antibody Discovery & Development, Isogenica
10.15 – 10.30

VIRTUAL COFFEE BREAK | NETWORK TABLES WITH SPEAKERS

10.30 – 11.10 Approaches to maximize successful development of cell lines expressing a diverse range of proteins
Dr. Alison Porter | Head of Expression System Sciences, Lonza
11.10 – 11:35 The CB307 Humabody journey: From Molecule to Medicine
Dr. Julia Pizzey | Director CMC Analytical Development, Crescendo Biologics
11:35 – 12.00 A step forward – combined strategies to enhance the performance of Pichia pastoris for the development of novel biotherapeutics
Dr. Joachim Klein | Head of Strain Development and Cell Banking, Microbial Development Services, Lonza
12.00 – 12.40 VIRTUAL NETWORKING LUNCH NETWORKING TABLES WITH SPEAKERS
12.40 – 13.00

AI-Augmented Drug Discovery
Dr. Murat Tunaboylu | CEO, Antiverse   

13.00 – 13.20

Unlocking the next generation of antibody drug conjugate cancer therapeutics
Dr. Myriam Ouberai | Founder and CEO, Spirea

13:20 – 13:40

KnotBody technology: Antibody-like modulators of ion channels by fusing venom-derived peptides into antibody CDR loops
Dr. John McCafferty | Founder and CEO, Maxion Therapeutics

13:45 – 13:50

WRAP UP AND END OF SYMPOSIUM

  

Register Here